Karlsen TH, Sheron N, Zelber-Sagi S, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116.PubMed
Karlsen TH, Rutter H, Carrieri P, et al. The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality. Lancet 2024;403:1522-1524.PubMed
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 2024.PubMed
Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023.PubMed
Kanwal F, Neuschwander-Tetri BA, Loomba R, et al. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology 2024;79:1212-1219.PubMed
EASL. Management of alcohol-related liver disease. J Hepatol 2018;69(1):154-181.PubMed
Francque SM, Marchesini G, Kautz A, et al. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322.PubMed
de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol 2022;76:959-974.PubMed
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis, 2021 update. J Hepatol 2021;75:659-689.PubMed
Dietrich CF, Bamber J, Berzigotti A, et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version). Ultraschall Med 2017;38:377-394.PubMed
Barr RG, Wilson SR, Rubens D, et al. Update to the Society of Radiologists in Ultrasound Liver Elastography Consensus Statement. Radiology 2020;296:263-274.PubMed
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol 2025;82:315-374.PubMed
EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 2022;76:1151-1184.PubMed
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69:406-460.PubMed
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol 2022;77:807-824.PubMed
EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019;70:172-193.PubMed
Lai JC, Tandon P, Bernal W, et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;74:1611-1644.PubMed
Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. Endocr Pract 2022;28:528-562.PubMed
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237-264.PubMed
Ferraioli G, Barr RG, Berzigotti A, et al. WFUMB Guideline/Guidance on Liver Multiparametric Ultrasound (MPUS), Part 1: Update on Liver Elastography. Ultrasound Med Biol 2024;50:1071-1087.PubMed
Studier og oversiktsartikler
Vesterhus M, Jorgensen KK, Frigstad SO, et al. [We need a new strategy for liver disease]. Tidsskr Nor Laegeforen 2022;142.
Targher G, Valenti L, Byrne CD. Metabolic Dysfunction-Associated Steatotic Liver Disease. N Engl J Med 2025;393:683-698.PubMed
WHO. Global status report on alcohol and health 2018. 2018.
Haldar D, Kern B, Hodson J, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. J Hepatol 2019;71:313-322.PubMed
Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Addiction 2010;105:?PubMed
Singal AK, Mathurin P. Diagnosis and Treatment of Alcohol-Associated Liver Disease. JAMA 2021;326:165-176.PubMed
Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019;393:1597-1608.PubMed
Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med 2024;390:497-509.PubMed
Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med 2025;392:2089-2099.PubMed
Tapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications. JAMA 2023;329:1589-1602.PubMed
